Low Dose Aspirin for Preeclampsia

Phase < 1

Recruiting

Research Sponsored by Anna Stanhewicz, PhD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at the study visit, an average of 4 hours

Awards & highlights

No Placebo-Only Group

Summary

This trial seeks to determine whether taking low dose aspirin (LDA) can reduce long-term risk of cardiovascular disease in women who had preeclampsia during pregnancy.

Who is the study for?

This trial is for women aged 18 or older who are 12 weeks to 5 years postpartum. It's suitable for those with a history of normal pregnancy or preeclampsia, regardless of low dose aspirin use during pregnancy. Women currently on daily aspirin, with skin diseases, tobacco use, certain chronic diseases like reduced kidney function, using cholesterol medications or antihypertensives, prior hypertension or gestational diabetes, current pregnancy, underweight BMI (<18.5), or allergies to study materials and drugs cannot participate.

What is being tested?

The study investigates how low dose aspirin therapy affects blood vessel function after childbirth in women who had preeclampsia. Researchers will examine the microvascular function in the skin using intradermal microdialysis to deliver Acetylcholine and Endothelin-1 locally and analyze inflammatory cells from drawn blood.

What are the potential side effects?

While not explicitly listed in the provided information, common side effects associated with similar procedures may include minor pain at injection sites, potential bruising or bleeding where blood is drawn; allergic reactions could occur if sensitivity to applied substances exists.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at the study visit, an average of 4 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at the study visit, an average of 4 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and at the study visit, an average of 4 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

microvascular endothelial function

microvascular endothelin-1-mediated constriction

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: assessment of microvascular functionExperimental Treatment2 Interventions

The investigators use intradermal microdialysis to deliver acetylcholine, acetylcholine + L-NAME, endothelin-1, endothelin-1 + BQ-788, and endothelin-1 + BQ-123 to the cutaneous microvasculature.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Acetylcholine

2013

Completed Phase 2

~220

Endothelin-1

2008

N/A

~20